Русский
Experience of using mometasone in seasonal allergic rhinitis patients
DOI: https://dx.doi.org/10.18565/therapy.2024.7.58-62
Gappoeva E.T.
North Ossetian State Medical Academy of the Ministry of Healthcare of Russia, Vladikavkaz
The aim: to evaluate the efficacy and safety of mometasone (mometasone fuorate nasal spray dosed 50 mcg/dose) when administered intranasally in adult patients with persistent seasonal AR (SAR).
Material and methods. An open, prospective, single-center, uncontrolled study of the efficacy and safety of intranasal mometasone at a daily dose of 200 mcg was performed. It involved 58 patients (mean age 36.8 ± 11.2 years) with a diagnosis of seasonal persistent AR of moderate severity clinical course. The duration of the study was 14 days. The criterion for assessing the efficacy of therapy was dynamics of AR symptoms in accordance with the total nasal symptom scale (TNSS), visual analogue scale (VAS), assessment of the quality of life using life quality questionnaire for patients suffering from rhinoconjunctivitis (RQLQ), assessment of the overall efficacy of therapy by the patient and the doctor after 14 days of therapy. The safety of the medicine was estimated by recording adverse events.
Results. As a result of treatment, a significant reduction of nasal symptoms according to TNSS scale was registered by 70.8% (p < 0.05). The mean VAS score was 63.9% lower than the baseline value (p < 0.05). The average total score on the RQLQ questionnaire decreased by 78.2% (p < 0.05). The study drug demonstrated high safety and good tolerability.
Conclusion. The results of the study showed that mometasone metered nasal spray has clinically significant efficacy and safety in the treatment of SAR in adult patients.
Literature
1. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014; 9: 963–74. https://doi.org/10.2147/COPD.S67283. PMID: 25246783. PMCID: PMC4166963. 2. Клинические рекомендации. Аллергический ринит. Российская ассоциация аллергологов и клинических иммунологов, Национальная медицинская ассоциация оториноларингологов, Союз педиатров России. Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 261. Доступ: http://cr.rosminzdrav.ru/schema/261_1 (дата обращения – 16.09.2024). (Clinical guidelines. Allergic rhinitis. Russian Association of Allergists and Clinical Immunologists, National Medical Association of Otorhinolaryngologists, Russian Union of Pediatricians. Rubricator of clinical recommendations of the Ministry of Healthcare of Russia. 2020. ID: 261. URL: http://cr.rosminzdrav.ru/schema/261_1 (date of access – 16.09.2024) (In Russ.)). 3. Pfaar O., Demoly P., Gerth van Wijk R. et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: An EAACI Position Paper. Allergy. 2014; 69(7): 854–67. https://doi.org/10.1111/all.12383. PMID: 24761804. 4. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственных препаратов с МНН мометазон в форме спрея назального дозированного 50 мкг/доза. Доступ: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=мометазон&lf=спрей&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1 (дата обращения – 16.09.2024). (State register of medicines of the Ministry of Healthcare of Russia. Instructions for the medical use of medicinal products with the INN mometasone in the form of a nasal spray dosed 50 mcg/dose. URL: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=мометазон&lf=спрей&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0®type=1%2c6&pageSize=10&order=Registered&orderType=desc&pageNum=1 (date of access – 16.09.2024) (In Russ.)). 5. Juniper E.F., Guyatt G.H., Griffith L.E., Ferrie P.J. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996; 98(4): 843–45. https://doi.org/10.1016/s0091-6749(96)70135-5. PMID: 8876562. 6. Lamb C.E., Ratner P.H., Johnson C.E. et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006; 22(6): 1203–10. https://doi.org/10.1185/030079906X112552. PMID: 16846553.
About the Autors
Elvira T. Gappoeva, MD, Dr. Sci. (Medicine), head of the Department of otorhinolaryngology and ophthalmology, North Ossetian State Medical Academy of the Ministry of Healthcare of Russia. Address: 362019, Vladikavkaz, 40 Pushkinskaya St.
E-mail: elvira907@mail.ru
